Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership
TipRanksApr 26 02:01 ET
Nanobiotix FY 2023 GAAP EPS $(1.17) Beats $(1.66) Estimate, Sales $39.323M Beat $13.680M Estimate
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.66) by 29.52 percent. This is a 32.37 percent increase over losses of $(1.73) p
BenzingaApr 24 17:42 ET
Nanobiotix Sa ADR Reports Promising 2023 Progress
TipRanksApr 24 17:27 ET
Nanobiotix 2023 Rev EUR36.2M >NANO.FR
Nanobiotix 2023 Rev EUR36.2M >NANO.FR
Dow JonesApr 24 16:41 ET
Press Release: NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results -- Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen"
Dow JonesApr 24 16:40 ET
Nanobiotix Sa ADR Sets Q4 and Full Year Results Date
TipRanksApr 17 16:57 ET
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
GlobeNewswireApr 17 16:15 ET
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday. Shares of CarMax, Inc. (NYSE:KMX) fell sharply in today's pre-market trading after the company r
BenzingaApr 11 08:03 ET
Nanobiotix Sa ADR Updates Share Capital Info
TipRanksApr 11 04:40 ET
Nanobiotix Announces Completion Of Phase 1 Dose Escalation And NBTXR3 Recommended Phase 2 Dose For The Treatment Of Inoperable, Recurrent Lung Cancer In Patients Amenable To Re-Irradiation
Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer ("NSCLC") who have previously received definitive radiation therapyCo
BenzingaApr 2 16:17 ET
Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining by around 100 points on Monday. Shares of Logitech International S.A. (NASDAQ:LOGI) fell in today's pre-market trad
BenzingaMar 18 05:57 ET
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
BenzingaMar 11 10:37 ET
Nanobiotix to Present at Upcoming Investor Conferences in March
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
GlobeNewswireMar 6 16:15 ET
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
GlobeNewswireJan 31 16:15 ET
General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday. Shares of General Motors Company (NYSE:GM) rose sharply during Tuesday's session after the company reported
BenzingaJan 30 10:09 ET
UBS Keeps Their Buy Rating on Nanobiotix (NBTX)
TipRanksJan 30 04:25 ET
Nanobiotix Gets $20 Million Milestone Payment From Janssen
Cancer-focused late-clinical stage biotechnology company Nanobiotix (NANO.PA) received a $20 million milestone payment from Johnson & Johnson's (JNJ.F) Janssen Pharmaceutica subsidiary, according to a
MT NewswiresJan 30 00:57 ET
Press Release: Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOB
Dow JonesJan 29 16:15 ET
INVO, NAYA Announce New Board Members Ahead of Merger
Seeking AlphaJan 17 12:48 ET
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection With Merger With NAYA Biosciences, NAYA Announces New Board Directors
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public company and accelerate
GlobeNewswireJan 17 08:00 ET
No Data
No Data